NEW YORK (GenomeWeb News) – Akrivis Technologies today said that it has inked an agreement with United States Biological to co-develop, manufacture, and sell research products based on Akrivis' Z-Tect technology.

The Z-Tect technology is a nanotechnology-based technique for detecting unusually low levels of protein and molecular targets. According to the firms, the technology has "ultra-low limits of detection several thousand fold lower than currently achievable," and will make it possible to "vastly improve the early detection of cancer biomarkers in vitro."